曼恩斯特(301325.SZ):2024年公司將持續加大對平板塗布技術的研發投入
格隆匯3月6日丨曼恩斯特(301325.SZ)接受特定對象調研時表示,在顯示面板領域,高精密平板塗布設備長期被海外企業所壟斷,隨着下游應用行業的回暖以及國產替代需求的不斷提升,公司作為高精密狹縫式塗布技術方案提供商,有望同步受益。2024年,公司將持續加大對平板塗布技術的研發投入,積極籌建中試平台,同時保持與下游應用企業、科研院校的緊密交流。近日,公司順利簽約了頭部顯示面板企業的塗布模頭訂單。未來,公司將以核心部件為切入點,積極推進公司智能裝備在顯示面板領域的迭代發展及規模化應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.